[go: up one dir, main page]

FI62087C - Foerfarande foer framstaellning av 1,2,3,4,10,14b-hexahydrobenso(c)pyrazino(1,2-a)pyridoazepinderivat med antihistamin- oc centralnervstimulerande aktivitet - Google Patents

Foerfarande foer framstaellning av 1,2,3,4,10,14b-hexahydrobenso(c)pyrazino(1,2-a)pyridoazepinderivat med antihistamin- oc centralnervstimulerande aktivitet Download PDF

Info

Publication number
FI62087C
FI62087C FI760884A FI760884A FI62087C FI 62087 C FI62087 C FI 62087C FI 760884 A FI760884 A FI 760884A FI 760884 A FI760884 A FI 760884A FI 62087 C FI62087 C FI 62087C
Authority
FI
Finland
Prior art keywords
formula
compound
mixture
group
salt
Prior art date
Application number
FI760884A
Other languages
English (en)
Finnish (fi)
Other versions
FI62087B (fi
FI760884A (fr
Inventor
Willem Jacob Van Der Burg
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19823518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI62087(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI760884A publication Critical patent/FI760884A/fi
Publication of FI62087B publication Critical patent/FI62087B/fi
Application granted granted Critical
Publication of FI62087C publication Critical patent/FI62087C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI760884A 1975-04-05 1976-04-01 Foerfarande foer framstaellning av 1,2,3,4,10,14b-hexahydrobenso(c)pyrazino(1,2-a)pyridoazepinderivat med antihistamin- oc centralnervstimulerande aktivitet FI62087C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
NL7504075 1975-04-05

Publications (3)

Publication Number Publication Date
FI760884A FI760884A (fr) 1976-10-06
FI62087B FI62087B (fi) 1982-07-30
FI62087C true FI62087C (fi) 1982-11-10

Family

ID=19823518

Family Applications (1)

Application Number Title Priority Date Filing Date
FI760884A FI62087C (fi) 1975-04-05 1976-04-01 Foerfarande foer framstaellning av 1,2,3,4,10,14b-hexahydrobenso(c)pyrazino(1,2-a)pyridoazepinderivat med antihistamin- oc centralnervstimulerande aktivitet

Country Status (17)

Country Link
US (1) US4062848A (fr)
JP (1) JPS5942678B2 (fr)
BE (1) BE840362A (fr)
CA (1) CA1076571A (fr)
CH (1) CH622261A5 (fr)
DE (1) DE2614406A1 (fr)
DK (1) DK142498B (fr)
ES (2) ES446634A1 (fr)
FI (1) FI62087C (fr)
FR (1) FR2305986A1 (fr)
GB (1) GB1543171A (fr)
HU (1) HU179401B (fr)
IE (1) IE42969B1 (fr)
LU (1) LU74680A1 (fr)
NL (2) NL189199C (fr)
SE (1) SE422941B (fr)
ZA (1) ZA761756B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPS6336682A (ja) * 1986-07-31 1988-02-17 Matsushita Electric Ind Co Ltd カセツト方式文字放送受信機
JPS63177670A (ja) * 1987-01-31 1988-07-21 Fujitsu General Ltd 文字放送受信装置
JPS63215179A (ja) * 1987-03-03 1988-09-07 Fujitsu General Ltd 受信装置
JPH055746Y2 (fr) * 1988-04-27 1993-02-15
NO175781C (no) * 1989-10-05 1994-12-07 Sankyo Co Analogifremgangsmåte for fremstilling av terapeutisk aktive tetracykliske forbindelser
EP0539164A1 (fr) * 1991-10-23 1993-04-28 Sankyo Company Limited Composés tétracycliques contenant l'azote ayant des propriétés antiallergiques et antiasthmatiques, leur préparation et utilisation
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
DE69913116T2 (de) * 1998-04-02 2004-06-03 Akzo Nobel N.V. Orale flüssige lösung enthaltend das antidepressivum mirtazapine
EP1178972A4 (fr) 1999-04-19 2002-06-12 Teva Pharma Nouvelle synthese de noyau piperazine
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
CA2368815A1 (fr) * 1999-04-19 2000-10-26 Claude Singer Nouvelle synthese et cristallisation de composes contenant de la piperazine
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
AU6476300A (en) * 1999-09-30 2001-05-10 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a piperazine derivative
WO2001038329A1 (fr) * 1999-11-24 2001-05-31 Sumika Fine Chemicals Co., Ltd. Cristaux de mirtazapine anhydre et leur procede d'obtention
WO2001042239A1 (fr) 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Procede de preparation d'un compose pyridinemethanol
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
EP1257278B1 (fr) 2000-02-11 2006-02-08 Akzo Nobel N.V. Utilisation de mirtazapine pour traiter des troubles du sommeil
IN190478B (fr) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
US6660730B2 (en) 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
WO2002064735A2 (fr) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methodes permettant d'ameliorer le traitement de depressions graves par genotypage visant a determiner le gene associe a l'apolipoproteine e4 et d'ameliorer la reponse therapeutique de personnes souffrant de depression grave et porteuses du gene associe a l'apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
JP2005501808A (ja) * 2001-03-01 2005-01-20 テバ ファーマシューティカル インダストリーズ リミティド ミルタザピン中間体の製造方法
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CZ296992B6 (cs) * 2002-10-03 2006-08-16 Zentiva, A.S. Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce
WO2004084905A2 (fr) * 2003-03-24 2004-10-07 University Of Florida Methodes de traitement de l'hyperhidrose idiopathique et de pathologies associees
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
CA2565996A1 (fr) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combinaison d'antipsychotiques atypiques et d'antagonistes du recepteur de 5-ht<sb>1b</sb>
EP1776160A1 (fr) * 2004-08-13 2007-04-25 Omeros Corporation Nouveaux ligands de recepteur de serotonine et leurs utilisations
WO2006023703A2 (fr) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Methode de traitement de troubles respiratoires lies au sommeil
JP4848704B2 (ja) * 2004-08-24 2011-12-28 住友化学株式会社 ２−（４−メチル−２−フェニルピペラジン−１−イル）−３−シアノピリジンの製造方法
US20080182987A1 (en) * 2004-08-24 2008-07-31 Sumitomo Chemical Company, Limited Method For Producing 2-(4-Methyl-2-Phenylpiperazine-1-Yl)-3-Cyanopiridine
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
WO2006055854A2 (fr) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methodes servant a limiter les effets secondaires d'un traitement par mirtazapine
US20090306046A1 (en) * 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
EP1904843A2 (fr) * 2005-07-08 2008-04-02 Braincells, Inc. Methodes destinees a identifier des agents et des conditions modulant la neurogenese
CN1939918B (zh) * 2005-09-30 2010-09-01 北京德众万全医药科技有限公司 一种米氮平的制备方法
WO2007047978A2 (fr) 2005-10-21 2007-04-26 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
WO2007055423A1 (fr) * 2005-11-14 2007-05-18 Sumitomo Chemical Company, Limited Procede de fabrication de 2-(4-methyl-2-phenylpiperazin- 1-yl)pyridine-3-methanol
EP1792618A1 (fr) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine pour le traitement de la douleur
EP1993556A1 (fr) * 2006-03-06 2008-11-26 N.V. Organon Méthode perfectionnée pour sevrer d'un traitement hormonal de symptômes vasomoteurs induits par un épuisement hormonal
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2382975A3 (fr) 2006-05-09 2012-02-29 Braincells, Inc. Neurogénèse par modulation d'angiotensine
CA2651862A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese induite par le recepteur 5ht
US20070270413A1 (en) * 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TW200815370A (en) * 2006-06-16 2008-04-01 Organon Nv Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (fr) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation de la neurogenèse par des ligands mélatoninergiques
AU2008204800A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
JP5192707B2 (ja) * 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
CN101679431B (zh) * 2007-04-11 2013-08-14 Msd欧斯股份有限公司 制备四环苯并氮杂卓的对映异构体的方法
US7994314B2 (en) * 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
EP2133350B1 (fr) * 2007-04-11 2016-03-23 Merck Sharp & Dohme B.V. Procédé de préparation de benzazépine pure énantiomorphiquement
US20080255348A1 (en) * 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
WO2008157094A1 (fr) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Amélioration de la tolérance à la mirtazapine et à un second principe actif par utilisation combinée de ces derniers
JP2009018992A (ja) * 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
WO2010046851A1 (fr) 2008-10-22 2010-04-29 Watson Pharma Private Limited Procédé amélioré de synthèse de mirtazapine et de ses intermédiaires
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102432594B (zh) * 2011-11-28 2013-09-11 山东鲁药制药有限公司 一种药物中间体1-（3-羟甲基吡啶-2-基）-2-苯基-4-甲基哌嗪的制备方法
CN103509020A (zh) * 2013-10-21 2014-01-15 山东鲁药制药有限公司 一种米氮平的合成方法
CN104356133A (zh) * 2014-11-25 2015-02-18 南京工业大学 一种制备抗抑郁药物米氮平的方法
JP6433809B2 (ja) * 2015-02-20 2018-12-05 株式会社トクヤマ １−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法
KR102540021B1 (ko) 2020-12-02 2023-06-07 (주)유케이케미팜 대량 생산에 적합한 미르타자핀의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (fr) * 1966-03-12
NL7202963A (fr) * 1972-03-07 1973-09-11
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation

Also Published As

Publication number Publication date
DK142498B (da) 1980-11-10
DK142498C (fr) 1981-07-06
HU179401B (en) 1982-10-28
CH622261A5 (fr) 1981-03-31
CA1076571A (fr) 1980-04-29
ZA761756B (en) 1977-03-30
NL940007I1 (nl) 1994-06-01
NL7504075A (nl) 1976-10-07
NL189199B (nl) 1992-09-01
FR2305986B1 (fr) 1980-06-13
JPS51122099A (en) 1976-10-25
FI62087B (fi) 1982-07-30
JPS5942678B2 (ja) 1984-10-16
SE7603931L (sv) 1976-10-06
GB1543171A (en) 1979-03-28
LU74680A1 (fr) 1976-11-11
NL940007I2 (nl) 1994-10-17
SE422941B (sv) 1982-04-05
FI760884A (fr) 1976-10-06
FR2305986A1 (fr) 1976-10-29
NL189199C (nl) 1993-02-01
US4062848A (en) 1977-12-13
DE2614406A1 (de) 1976-10-14
DK142676A (fr) 1976-10-06
ES446634A1 (es) 1977-11-01
AU1236176A (en) 1977-09-29
IE42969B1 (en) 1980-11-19
BE840362A (fr) 1976-10-04
ES459348A1 (es) 1978-03-16
IE42969L (en) 1976-10-05
DE2614406C2 (fr) 1992-02-20

Similar Documents

Publication Publication Date Title
FI62087C (fi) Foerfarande foer framstaellning av 1,2,3,4,10,14b-hexahydrobenso(c)pyrazino(1,2-a)pyridoazepinderivat med antihistamin- oc centralnervstimulerande aktivitet
JPS6134426B2 (fr)
EP0047226B1 (fr) Dérivés pipéridylidéniques, leur préparation et compositions pharmaceutiques les contenant
GB1593417A (en) Carbocyclic-fused pyrazolopyridine derivatives
JPS58152885A (ja) 薬理学的に活性なピラゾロ〔４，３−↓ｃ〕ピリジン類
DK157615B (da) Analogifremgangsmaade til fremstilling af terapeutisk aktive imidazo oe1,5-aaaoe1,4aa diazepin-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf
FI60563C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara tetracykliska piperidinoderivat
DE3780015T2 (de) Kondensierte heterocyclische tetrahydroaminochinolinole und verwandte verbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DE60218646T2 (de) N-biphenylcarbonyl- und n-phenylpyridylcarbonyl substituierte bi- und tricyclische azepine und diazepine als vasopressin-agonisten
CS207619B2 (en) Method of making the new derivatives of 5,11-dihydro-6h-pyrido 2,3-b 1,4 benzodiazepin-6-on
US4547496A (en) Antiulcer [1] benzepino[3,4-b]pyridine and compositions
JPH0322390B2 (fr)
FI91411B (fi) Menetelmä terapeuttisesti käyttökelpoisten 4,5,6,7-tetrahydroisotiatsolo/4,5-c/pyridiini-johdannaisten ja niiden isomeerien ja happoadditiosuolojen valmistamiseksi
SU1272990A3 (ru) Способ получени производных диазабицикло /3,3,1/ нонана или их солей
WO2002083685A1 (fr) Cyclohexylphenyles ayant une activite d&#39;agonistes de la vasopressine
Marchalin et al. Thienoquinolizidinones. Synthesis and rearrangement into new piperidino [1, 2‐a][1, 3] or [1, 4] diazepinones fused to a thiophene ring
RU2057754C1 (ru) Гетероциклические соединения или их кислотно-аддитивные соли
Huckle et al. 4-Amino-2, 3, 4, 5-tetrahydro-1-benzoxepin-5-ols, 4-amino-2, 3, 4, 5-tetrahydro-1-benzothiepin-5-ols, and related compounds
PL90057B1 (en) Piperdine derivatives[au6900774a]
Liepa A synthesis of alkylated 3-aminoisoquinolines and related compounds
US3985751A (en) Benzocycloheptaisoquinoline derivatives
US3555018A (en) Thiazinopyridoindolone derivatives
FI89361C (fi) Foerfarande foer framstaellning av farmaceutiskt anvaendbart 5,6,7,8-tetrahydro-4h-isoxazolo/4,5-c/azepinderivat
CA1082183A (fr) Composes a base de diazepino-dibenzoxazepine et de diazepinodibenzazepine tetracyclique a activite biologique
US3419568A (en) Derivatives of 1,2,3,4-tetrahydro-5h-pyrido[4,3b]indoles

Legal Events

Date Code Title Description
MA Patent expired
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L60

Extension date: 20010401

MA Patent expired

Owner name: AKZO N.V.